Actively Recruiting
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Led by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Updated on 2021-11-17
540
Participants Needed
1
Research Sites
300 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
CONDITIONS
Official Title
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 6518 years
- Diagnosed with adult rheumatoid arthritis according to the 2010 ACR/EULAR criteria
- Have received at least one dose of the study drugs
- Currently in follow-up at the rheumatology consultations of the University Hospital Virgen Macarena (HUVM)
- Have at least two complete clinical evaluations (baseline and final)
You will not qualify if you...
- Medical records lack sufficient baseline and final variables for analysis
- More than 50% of the required data variables are missing in records
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Universitario Virgen macarena
Seville, Spain, 41009
Actively Recruiting
Research Team
B
Blanca Estela Hernández Cruz
CONTACT
C
Carlos García Pérez
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here